K36 Therapeutics raised $70 million to help fund an ongoing clinical trial for its lead and only candidate, an oral multiple myeloma treatment.
The Cambridge, MA-based biotech on Wednesday revealed the new cash influx. The Series B was led by VC Nextech Invest and included Bristol Myers Squibb and all previous investors, such as Eight Roads Ventures, Atlas Venture and F-Prime Capital.
The biotech broke out of stealth back in December 2021, with $30 million from a Series A that closed earlier that year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters